LOVASTATIN AND THE HUMAN LENS - RESULTS OF A 2-YEAR STUDY

被引：17

作者：

CHYLACK, LT

MANTELL, G

WOLFE, JK

FRIEND, J

ROSNER, B

机构：

[1] The Center for Clinical Cataract Research and Department of Surgery, Brigham and Women’s Hospital, Department of Ophthalmology, Harvard Medical School, Boston, MA

[2] Merck Sharp and Dohme Research Laboratory, West Point, PA

[3] The Center for Clinical Cataract Research, Department of Surgery, Brigham and Women’s Hospital, Boston, MA

[4] The Channing Laboratory, Harvard Medical School, Boston, MA

[5] Center for Clinical Cataract Research, Brigham and Women’s Hospital, Boston, MA

[6] Merck Sharp and Dohme Research Laboratory, West Point, PA

来源：

OPTOMETRY AND VISION SCIENCE | 1993年 / 70卷 / 11期

关键词：

LENS; LOVASTATIN; HYPERCHOLESTEROLEMIA; LOCS II; IMAGE ANALYSIS;

D O I：

10.1097/00006324-199311000-00011

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Lovastatin has been associated with development of subcapsular cataract in dogs given high doses. To test the cataractogenic potential of lovastatin in humans, 192 patients were divided into 2 groups, A (N = 94) and B (N = 98), 1 taking 40 mg/day of lovastatin and 1 taking placebo. Both groups were enrolled for 2 years in this double-blind, randomized study and were followed with eye examinations including assessment of visual function, Lens Opacities Classification System II (LOCS II) cataract and nuclear color classification, and computerized lens image analysis. There were no statistically significant differences in visual function between the two groups. Similarly, cataract progression, assessed by LOCS II measurement and by computerized measurements of cataract, showed no important differences between the treatment groups. These data show no cataractogenic effect of lovastatin in humans.

引用

页码：937 / 943

页数：7

共 23 条

[1]

Bradford R.H., Shear C.L., Chremos A.N., Dujovne C., Franklin F.A., Gould A.L., Hesney M., Higgins J., Langenddrfer A., Pool J.L., Schnaper H., Stephenson W.P., Expanded Clinical Evaluation of Lovastatin (EXCEL) Study: Design and patient characteristics of a double-blind placebo-controlled study in patients with moderate hypercholesterolemia, Am J Cardiol, 66, pp. 44B-55B, (1990)

[2]

Mantell G., Burke M.T., Staggers J., Extended clinical safety profile of lovastatin, Am J Cardiol, 66, pp. 11B-15B, (1990)

[3]

Tobert J.A., Efficacy and long-term adverse effect pattern of lovastatin, Am J Cardiol, 62, pp. 28J-34J, (1988)

[4]

Gerson R.J., Macdonald J.S., Alberts A.W., Chen J., Yudkovitz J.B., Greenspan M.D., Rubin L.F., Bokelman D.L., On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors, Exp Eye Res, 50, pp. 65-78, (1990)

[5]

Fraunfelder F.T., Ocular examination before initiation of lovastatin (Mevacor) therapy, Am J Ophthalmol (Letter), 105, pp. 91-92, (1988)

[6]

Laties A.M., Keates E.U., Taylor H.R., Chremos A.N., Shear C.L., Lippa E.A., Gould A.L., Hurley D.P., The human lens after 48 weeks of treatment with lovastatin, N Engl J Med, 323, pp. 683-684, (1990)

[7]

Laties A.M., Shear C.L., Lippa E.A., Gould A.L., Taylor H.R., Hurley D.P., Stephenson W.P., Keates E.U., Tupy-Visich M.A., Chremos A.N., Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results II. Assessment of the human lens after 48 weeks of treatment with lovastatin, Am J Cardiol, 67, pp. 447-453, (1991)

[8]

Laties A., Keates E., Lippa E., Shear C., Snavely D., Tupy-Visich M., Chremos A.N., Field test reliability of a new lens opacity rating system utilizing slit-lamp examination, Lens Eye Toxicol Res, 6, pp. 443-464, (1989)

[9]

Chylack L.T., Leske M.C., McCarthy D., Khu P., Kashiwagi T., Sperduto R., Lens Opacities Classification System II (LOCS II), Arch Ophthalmol, 107, pp. 991-997, (1989)

[10]

Leske M.C., Chylack L.T., Wu S.-Y., The Lens Opacities Case-Control Study Group. The Lens Opacities Case-Control Study: Risk factors for cataract, Arch Ophthalmol, 109, pp. 244-251, (1991)

← 1 2 3 →